Sign Up to like & get
recommendations!
1
Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1096
Abstract: This study aimed to evaluate the bioequivalence of two pazopanib tablet formulations in healthy Chinese subjects. A randomized, open‐label, single‐dose, two‐period, two‐sequence, crossover study was conducted under fasting conditions. A total of 32 eligible subjects…
read more here.
Keywords:
pazopanib tablet;
chinese subjects;
tablet;
generic branded ... See more keywords